- CMS has launched the third RMADA contract vehicle with a $3.5 billion ceiling over five years
- Seventeen companies secured spots after a competition that drew 34 offers
- The contract supports research and analysis for Medicare, Medicaid, ACA and other healthcare initiatives
The Centers for Medicare & Medicaid Services has awarded 17 companies positions on the third iteration of the Research, Measurement, Assessment, Design and Analysis, or RMADA, blanket purchase agreement, a five-year vehicle with a shared ceiling of $3.5 billion supporting healthcare research and analytical services.
The Potomac Officers Club’s 2026 Healthcare Summit on Dec. 3 will bring together federal health leaders to discuss AI, digital modernization and other priorities shaping healthcare delivery and acquisition. Register today.
What Does the RMADA 3 Contract Cover?
According to the award notice published Wednesday on SAM.gov, the indefinite-delivery/indefinite-quantity contract will provide CMS with analytical support and technical assistance for healthcare models and demonstration programs associated with the Patient Protection and Affordable Care Act, Medicare, Medicaid, the Children’s Health Insurance Program and private payer initiatives.
The contract scope covers the design, implementation and evaluation of research, payment and service delivery models intended to reduce healthcare expenditures while maintaining or enhancing quality of care.
Which Companies Received Awards?
CMS received 34 offers and selected 17 companies for RMADA 3. The awardees are:
- Abt Global
- Acumen
- American Institutes for Research
- Arbor Research Collaborative for Health
- Actuarial Research Corp.
- Booz Allen Hamilton
- Deloitte Consulting
- General Dynamics Information Technology
- Guidehouse
- L&M Policy Research
- The Lewin Group
- Livanta, now part of Commence
- Mathematica
- National Opinion Research Center at the University of Chicago
- RTI International
- Tria Federal
- Westat
Guidehouse, L&M Policy Research, Livanta and Tria Federal are new awardees, while the remaining companies are incumbents. CMS noted that additional awardees may be announced later under the BPA’s award structure.
The awards follow CMS’ February request for industry input on RMADA 3, which outlined the vehicle’s $3.5 billion ceiling and scope supporting healthcare research, payment models and demonstration programs. RMADA 3 succeeds the $5 billion RMADA 2 vehicle, which CMS awarded to 17 companies in 2019 and is scheduled to expire July 31.
